As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Study of Omega-3 Replacement with Krill Oil in Treatment of Systemic Lupus Erythematosus
The study is a 24 week randomized, double-blind controlled multicenter study followed by an open label extension treatment for another 24 weeks. The purpose of this study is to determine whether the correction of the omega-3 deficiency may reduce disease activity in SLE patients.
In order to participate you must meet the following criteria:
- Have a clinical diagnosis of systemic lupus erythematosus (SLE).
You will be excluded from the study if any of the following criteria apply to you:
- Have rapidly progressive neurologic or renal disease.
- Are using an omega-3 prescription drug (e.g. Lovaza®, Vascepa®, etc.) or as medical food (e.g. Vascazen®, Vayarin, Onemia™ etc.).
- Are currently using or have recently used (within 3 months of screening) any OTC fish or krill oil dietary supplement, or any long-chain omega-3 fatty acid dietary supplement (e.g., MegaRed).
This is a partial list of inclusion and exclusion criteria.